Secukinumab is Dominant Vs. TNF-Inhibitors in the Treatment of Active Ankylosing Spondylitis- Results from a Turkish Cost-Effectiveness Model
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.768
https://www.valueinhealthjournal.com/article/S1098-3015(17)31102-6/fulltext
Title :
Secukinumab is Dominant Vs. TNF-Inhibitors in the Treatment of Active Ankylosing Spondylitis- Results from a Turkish Cost-Effectiveness Model
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31102-6&doi=10.1016/j.jval.2017.08.768
First page :
A534
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
733